key: cord-0710537-xafq2v0i
authors: Dent, Matthew; Hamorsky, Krystal; Vausselin, Thibaut; Dubuisson, Jean; Miyata, Yoshinari; Morikawa, Yoshio; Matoba, Nobuyuki
title: Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model
date: 2020-08-27
journal: Cell Mol Gastroenterol Hepatol
DOI: 10.1016/j.jcmgh.2020.08.009
sha: 6234f97573b92244c727258fa624e12d86166431
doc_id: 710537
cord_uid: xafq2v0i

Background Infection with hepatitis C virus (HCV) remains to be a major cause of morbidity and mortality worldwide despite the recent advent of highly effective direct-acting antivirals. The envelope glycoproteins of HCV are heavily glycosylated with a high proportion of high-mannose glycans (HMGs), which serve as a shield against neutralizing antibodies and assist in the interaction with cell-entry receptors. However, there is no approved therapeutic targeting this potentially druggable biomarker. Methods The anti-HCV activity of AvFc was evaluated through the use of in vitro neutralization assays as well as an in vivo challenge in the PXB chimeric human liver mouse model. Drug toxicity was assessed by histopathology, serum ALT, and mouse body weights. Results AvFc was capable of neutralizing cell culture-derived HCV in a genotype-independent manner, with IC50 values in the low nanomolar range. Systemic administration of AvFc in a histidine-based buffer was well tolerated; after 11 doses every other day at 25 mg/kg there were no significant changes in body or liver weights or in blood human albumin or serum ALT activity. Gross necropsy and liver pathology confirmed the lack of toxicity. This regimen successfully prevented genotype 1a HCV infection in all animals, while an AvFc mutant lacking HMG binding activity failed. Conclusion These results suggest that targeting envelope HMGs is a promising therapeutic approach against HCV infection, and AvFc may provide a safe and efficacious means to prevent recurrent infection upon liver transplantation in HCV-related end-stage liver disease patients.

Hepatitis C virus (HCV) is an enveloped monopartite positive sense ssRNA virus in the family 73 transplantation may be a last resort [15] . Moreover, recurrent infection occurs universally and rapidly 97 post liver transplantation [16, 17] , which increases the risk of accelerated cirrhosis, graft failure and 98 death [18] . DAAs, by their nature, cannot prevent recurrent infection. Therefore, alternative or 99 complementary therapies to DAAs that can block viral entry to target cells, such as antibodies or other 100 molecules acting alike, may need to be considered in these circumstances [18, 19] . However, there is 101 currently no entry inhibitor approved for HCV treatment. 102

The HCV envelope proteins E1 and E2 are heavily glycosylated and, like glycoproteins of other 103 enveloped viruses (HIV and the coronaviruses, for instance), have a high proportion of high-mannose-104 type N-glycans (HMGs) on their surface [20] [21] [22] . These glycans are typically processed to hybrid and 105 complex forms on glycoproteins secreted by healthy cells [23] . Thus, the HMGs on the surface of HCV 106 may be considered a druggable target. We have previously described the development of an HMG-107 targeting lectin-Fc fusion protein, or "lectibody", called Avaren-Fc (AvFc), which was shown to bind with 108 high affinity to clusters of HMGs on the HIV envelope protein gp120 and effectively neutralize multiple 109 HIV clades and groups including HIV-2 and simian immunodeficiency virus [24] . Further analysis 110 indicated that AvFc can bind to HCV E2 protein [24] . Therefore, in this study, we aim to investigate the 111 anti-HCV therapeutic potential of AvFc in in vitro neutralization assays and an in vivo HCV challenge 112 study using PXB-mice®, a chimeric uPA/SCID mouse model transplanted with human hepatocytes 113 (reviewed in: [25] ). 114 115 J o u r n a l P r e -p r o o f

Building on our previous observation that AvFc has affinity to a recombinant HCV E2 envelope 118 protein [24], we first examined whether AvFc inhibits HCV infection in vitro using multiple genotypes of 119 cell culture-produced virus (HCVcc) or pseudotyped virus (HCVpp). AvFc significantly blocked the 120 infection of the human liver cell line Huh-7 by HCVcc from genotypes 1a, 2a, 4a, 5a, and 6a, with 50% 121 inhibitory concentration (IC 50 ) values in the low nanomolar range ( Table 1 and Figure 1A ). Compared to 122

Avaren monomer, AvFc overall showed approximately 2-log higher activity, while no inhibitory effect 123 was observed for a plant-produced anti-HIV broadly neutralizing antibody VRC01 that shares the same 124 human IgG1 Fc region with AvFc [26] . Additionally, Avaren and AvFc, but not VRC01, effectively 125 neutralized HCVpp harboring a murine leukemia virus backbone, suggesting that the lectin and the 126 lectibody act as an entry inhibitor ( Figure 1B) . 127 128

Previously, we found that AvFc has limited solubility in phosphate-buffered saline (PBS) at 130 concentrations above 1 mg/mL (unpublished observation). In order to facilitate in vivo studies we 131 screened for an optimal liquid formulation for systemic administration that can impart improved 132 stability and solubility to AvFc at higher concentrations. Initial buffer screening revealed that AvFc is 133 prone to degradation at and below pH 6.5, suggesting that AvFc is not stable in acidic pH conditions 134 ( Figure 2, Table 2 ). Further pre-formulation studies led us to identify an optimal buffer composed of 30 135 mM histidine, pH 7.0, 100 mM sucrose and 100 mM NaCl. Although AvFc showed comparable T m in the 136 histidine buffer and PBS in differential scanning fluorimetry (62.49 ± 0.13°C vs. 62.68 ± 0.25°C; Figure while showing a significant concentration decrease concomitant with increasing turbidity in PBS ( Figure  141 3C), further demonstrating the histidine buffer's superiority for AvFc formulation. 142 143

To determine an optimal dosing regimen for an HCV challenge experiment, a pharmacokinetic 145 analysis of AvFc was conducted in C57bl/6 mice. After a single i.p. injection of AvFc at a dose of 25 146 mg/kg, peak drug concentration was observed between 2 and 4 h, with a half-life of 24.5 h in male and 147 18.5 in female animals (Figure 4) . After 48 h, in both male and female animals the plasma concentration 148 of AvFc remained above a target trough concentration of 130 nM (10 μg/mL), at which AvFc showed 149 >90% neutralization effects against HCV (see Figure 1 ). Consequently, these results suggested that 150 administration of the drug every other day (Q2D) might be sufficient to keep the virus under control in a 151 murine HCV challenge model. 152

We then assessed the safety of Q2D administration of AvFc in PXB-mice®. To effectively discern 153 potential toxicity associated with AvFc's HMG-binding activity, we included an AvFc variant lacking HMG-154 binding activity as a control (AvFc lec-; Figure 5A , B). PXB mice received either the vehicle (the histidine 155 buffer described above) Q2D for 11 total doses, AvFc at 25 mg/kg Q2D for a total of 8 or 11 doses, or 156

AvFc lecat 25 mg/kg Q2D for 11 total doses. As shown in Figure 6A -C, no significant differences in either 157 body weights, blood h-Alb levels or serum ALT activity were observed. Additionally, no significant 158 differences in relative liver weight were seen ( Figure 6D) . These results indicate that AvFc, formulated in 159 the histidine buffer, is well tolerated in the immunocompromised mice engrafted with human 160 hepatocytes. 161

Histopathology was performed to evaluate any potential toxicity to the human liver grafts due 162 to AvFc administration (Table 3 and Figure 7) . In the human hepatocyte area, slight to moderate (score 2 163 mouse, was observed in all mice including the vehicle-treated group (Figure 7A-C) . Minimal 165 inflammatory cell infiltration around vacuolated hepatocytes (Score 1) was seen in one mouse each 166 from the 11 dose AvFc and AvFc lecgroups ( Figure 7D, E) ; however, this was unlikely treatment-related 167 as a similar change is occasionally seen in PXB-Mice (PhoenixBio, unpublished observation). No AvFc 168 treatment-specific change was observed, except for an incidental build-up of pigmentation found in the 169

Glisson's sheath in the liver of one mouse ( Figure 7F) . Collectively, it was concluded that there was no 170 treatment-related adverse effect in the liver tissue. The full pathology report may be found in the 171 Supplementary Information. 172 173

Lastly, we assessed AvFc's protective efficacy against HCV infection in vivo using the treatment 175 regimen described above. PXB mice were inoculated i.p. with a genotype 1a virus along with initial 176 treatment with 25 mg/kg of AvFc or AvFc lecon day 0. As shown in Figure 8A , AvFc lec--treated mice 177 showed high serum HCV RNA levels from day 7 post challenge through the end of the study on day 35. In 178 sharp contrast, animals treated with both 8 and 11 doses of AvFc did not show any quantifiable level 179 (4.0 x 10 4 copies/mL) of HCV RNA in sera, indicating that the lectibody prevented the infection of human 180 liver grafts by the virus. Similar to the results in Figure 3 , overall no major toxicity signal was noted in 181 body weights, h-Alb or h-ALT levels between the test groups although there was a temporal drop in 182 body weight and h-Alb in one of the AvFc-treated group at an early timepoint, indicating that the liver 183 grafts remained functional over the course of the study (Figure 8B-D) . 184 independent anti-HCV activity. Additionally, systemic administration of AvFc effectively protected 188 chimeric human-mouse liver mice from infection with a genotype 1a virus without apparent toxicity, 189 providing the first in vivo proof-of-concept for the lectibody's antiviral potential. 190

The mechanism of HCV neutralization by AvFc is likely through binding to HMGs on the E1/E2 191 envelope protein dimer, which blocks their interaction with host cell receptors and viral entry. Unlike 192 HIV envelope glycoproteins, whose glycan content can vary widely between strains, the number and 193 position of glycosylation sites on E1/E2 are highly conserved, indicating their critical role in HCV's 194 infectious processes [27] . The notion that AvFc functions as an entry inhibitor is supported by the facts 195 that the lectibody has affinity to the E2 protein [24] and that other mannose-binding lectins, such as 196 Griffithsin or Cyanovirin-N, inhibit entry in this manner [28, 29] . AvFc inhibited multiple genotypes of 197 HCV with an average IC 50 over 100-fold lower than that of the monomer Avaren lectin (Table 1) The present study also demonstrated that AvFc therapy is well tolerated in mice and human 207 hepatocytes, as Q2D i.p. administration of 25 mg/kg of AvFc up to 11 doses did not show any obvious 208 toxicity in PXB mice by gross necropsy or histopathology of engrafted human hepatocytes, nor did it 209 result in significant changes in body weight, h-Alb, or ALT levels (Figure 6, 7) . This corroborates our 210 previous observation that AvFc administration, both i.p. and intravenously, was well tolerated and 211 produced no toxicity in mice, rats, and rhesus macaques [24] . We hypothesize that the lack of any 212 significant toxicity is attributable to AvFc's unique HMG-binding mechanism, whereby it requires 213 multivalent interaction with several HMGs in proximity to exhibit high affinity binding to a glycoprotein be less susceptible to amino acid mutations because it targets the glycan shield of the virus rather than a 249 specific epitope. Deletions of glycans, even if occurring following prolonged exposure to a carbohydrate-250 binding agent like AvFc, may result in significant decrease in viral fitness by decreasing E1/E2 251 incorporation into HCV particles or increased susceptibility to humoral immunity due to breach in the 252 glycan shield [27, 42] . Our results provide a foundation to test the above hypotheses and feasibility of 253 the HMG-targeting anti-HCV strategy. Of note, a unique advantage of AvFc over the two antibody-based 254 entry inhibitor candidates described above is that the lectibody has the capacity to neutralize both HIV 255

[24] and HCV (present study). Accordingly, AvFc may provide an effective means (e.g., pre-exposure The H77/JFH1 chimera, which expresses the core-NS2 segment of the genotype 1a polyprotein within a 287 genotype 2a background, has been described previously [ and phosphate buffers at pH 4.5 -7.5 (see Table 2 ). All the buffer agents were purchased from 298

MilliporeSigma. AvFc was diafiltrated and adjusted to 1 mg/mL (or 62.5 μM) in respective buffers. 299

Stability was evaluated by SDS-PAGE following incubation for 2 weeks at 37°C. The melting temperatures 300 of AvFc were determined by differential scanning fluorimetry performed on an Applied Biosystems 301

StepOnePlus RT-PCR system as described previously 3) and 5.5 (Lane 4), citrate at pH 5.0 (Lane 5) and 6.0 (Lane 6), succinate at pH 5.5 (Lane 7) and 6.5 (Lane 561 8), histidine at pH 6.0 (Lane 9) and 7.0 (Lane 10), phosphate at pH 6.5 (Lane 11), 7.0 (Lane 12) and 7.5 562 (Lane 13), tris at pH 7.5 (Lane 14), and PBS (Lane 15). At pH 6.0 and below (buffers 1-9), AvFc exhibited 563 significant degradation after two weeks at 37°C. AvFc did not significantly degrade in buffers 10-15, and 564 therefore these were chosen for further pre-formulation analysis. MW: molecular weight marker. S: 565 standard AvFc control. 30 mM Succinate (4.86 g/L NaOOCCH 2 CH 2 COONa )* 6.5 9 30 mM Histidine (4.65 g/L C 6 H 9 N 3 O 2 )* 6.0 10 30 mM Histidine (4.65 g/L C 6 H 9 N 3 O 2 )* 7.0 11 30 mM Phosphate (2.89 g/L NaH 2 PO 4 · H 2 O, 2.42 g Na 2 HPO 4 · 7 H 2 O) 6.5 0  0  0  0  0  0  0  0  0  0  0  0  0  0  0  Human hepatocytes  Fatty change,  macrovesicular  2  3  3  3  3  3  3  3  3  3  3  3  3  3  3 Infiltrate, inflammatory cell, around vacuolated hepatocyte 

Structural biology of hepatitis C virus

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a 367 modelling study

Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug

Use

Increases in hepatitis C virus infection related to injection 373 drug use among persons aged≤ 30 years-Kentucky

Hepatitis C virus 376 infection

Extrahepatic morbidity and 378 mortality of chronic hepatitis C

Peginterferon alfa-2b plus ribavirin compared with interferon 381 alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Prevention of allograft HCV recurrence with peri-transplant human monoclonal 483 antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept 484 study

The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific

Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape 490 from broadly neutralizing antibodies

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy

Epidemiology of hepatitis C virus in HIV-infected patients

Challenges Facing a Rural Opioid 496 Epidemic: Treatment and Prevention of HIV and Hepatitis C

Expanding deceased donor kidney transplantation: medical risk, infectious 499 risk, hepatitis C virus, and HIV

Liver Transplantation Today: Where We Are Now and Where We Are

AvFc 594 monomer is seen at 38.5 kDa and, whereas under NR conditions, AvFc dimer (via inter-polypeptide 595 disulfide bonds in the Fc region) appears at 77 kDa. (B) Surface plasmon resonance analysis of HCV E2-596 binding affinity of AvFc and AvFc lec-. A recombinant E2 protein (Immune Technology Corp.) was 597 immobilized to a CM5 chip using amine coupling to a surface density of ≈ 200 RU. AvFc or AvFc lec-was 598 then injected over the chip surface at a rate of 30 μL/min for 120 seconds followed by a 600 second 599 dissociation period

Binding affinity could not be determined for AvFc lec-due to lack of measurable binding

Toxicological analysis of systemically administered AvFc in the PXB® human liver chimeric 604 mouse model. PXB mice were administered i.p. with AvFc or AvFc lec-at 25 mg/kg (n=4 each), or the 605 histidine buffer vehicle control (n=3) every 2 days (Q2D) and monitored for body weights, blood human 606 albumin (h-Alb) levels and serum alanine aminotransferase (ALT) levels over 42 days. (A) Percent change 607 of body weights from the initial day of dosing (Day 0). (B) Blood h-Alb levels

Each data point represents 609 mean ± SEM (A-C) and individual data with mean ± SEM (D) in each group. No significant changes in any 610 of the safety endpoints were noted between the groups (A-C: two-way analysis of variance (ANOVA); D: 611 one-way ANOVA). Tris (3.63 g/L NH 2 C(CH 2 OH) 3 )* 7